New combo aims to overcome resistance in Late-Stage lung cancer
NCT ID NCT04467723
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study tests whether adding pirfenidone to the immunotherapy drug atezolizumab can improve tumor shrinkage and reduce treatment resistance in people with stage 4 or recurrent non-small cell lung cancer. About 25 adults who have already tried at least one prior treatment will receive the combination. The main goal is to check safety and side effects, while also measuring how well the cancer responds and how long people live.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Kansas Cancer Center (KUCC)
NOT_YET_RECRUITINGFairway, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Kansas Cancer Center, Westwood Campus
RECRUITINGKansas City, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.